The role of MAPK signaling, as a target for prostate cancer therapy, becomes complicated as others report that MAPK signaling may be inhibited in advanced prostate cancer due to the deletion of the PTEN [110–112]. This evidence concerns the gene PTEN and prostate carcinoma.